Cargando…
Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Metastatic disease is responsible for most of cancer lethality. A main obstacle for therapy of advanced cancers is that the outcome of metastasis depends on a complex interplay between malignant and host cells. The perioperative period represents an underutilized window of opportunity for cancer tre...
Autores principales: | Alonso, D.F, Ripoll, G.V, Garona, J, Iannucci, N.B, Gomez, D.E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257748/ https://www.ncbi.nlm.nih.gov/pubmed/21470136 http://dx.doi.org/10.2174/138920111798377076 |
Ejemplares similares
-
Anticancer activity of repurposed hemostatic agent desmopressin on AVPR2-expressing human osteosarcoma
por: Sobol, Natasha Tatiana, et al.
Publicado: (2021) -
Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model
por: Ripoll, Giselle V., et al.
Publicado: (2013) -
The novel desmopressin analogue [V(4)Q(5)]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models
por: GARONA, JUAN, et al.
Publicado: (2015) -
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients
por: Weinberg, Ruth S, et al.
Publicado: (2015) -
Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial
por: Iseas, Soledad, et al.
Publicado: (2020)